AC Immune SA (ACIU)
Stock Price Chart
Key Info
| Market Cap | 481.46M |
| Revenue (ttm) | 114.46M |
| Net Income (ttm) | 46.85M |
| Shares Out | 71.86M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $6.70 |
| Previous Close | $6.60 |
| Change ($) | 0.10 |
| Change (%) | 1.52% |
| Day's Open | 6.60 |
| Day's Range | 6.55 - 6.84 |
| Day's Volume | 240,843 |
| 52-Week Range | 4.07 - 13.00 |
More Stats
| Market Cap | 481.46M |
| Enterprise Value | 186.48M |
| Earnings Date (est) | Nov 17, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 71.86M |
| Float | 26.86M |
| EPS (basic) | n/a |
| EPS (diluted) | -0.55 |
| FCF / Share | 0.81 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 11.42% |
| Payout Ratio | n/a |
| Shares Short | 627,105 |
| Short Ratio | 9.40 |
| Short % of Float | 2.29% |
| Beta | 0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | 8.76 |
| PS Ratio | 4.21 |
| PB Ratio | 1.74 |
| Revenue | 114.46M |
| Operating Income | 45.91M |
| Net Income | 46.85M |
| Free Cash Flow | 54.99M |
| Net Cash | 294.97M |
| Net Cash / Share | 4.10 |
| Gross Margin | 100.00% |
| Operating Margin | 40.11% |
| Profit Margin | 40.90% |
| FCF Margin | 48.04% |
| ROA | -4.77% |
| ROE | -10.18% |
| ROIC | 80.10% |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|
| Revenue | 111 | 7.19 | 20.26 | 23.21 | 39.09 | 30.27 |
| Revenue Growth | 1443.31% | -64.48% | -12.75% | -40.61% | 29.14% | - |
| Gross Profit | 111 | 7.19 | 20.26 | 23.21 | 39.09 | 30.27 |
| Operating Income | 44.54 | -49.55 | -22.54 | -10.46 | 18.62 | 10.72 |
| Net Income | 45.44 | -50.95 | -26.41 | -7.10 | 20.27 | 10.74 |
| Shares Outstanding | 67.56 | 57.36 | 57.08 | 50.10 | 43.41 | 42.68 |
| Earnings Per Share | 0.64 | -0.82 | -0.46 | -0.14 | 0.44 | 0.24 |
| EPS Growth | - | - | - | - | 83.33% | - |
| Operating Cash Flow | 55.23 | -43.77 | -22.27 | -5.56 | 44.04 | -17.64 |
| Capital Expenditures | -1.89 | -1.86 | -1.80 | -0.90 | -0.24 | -0.13 |
| Free Cash Flow | 53.34 | -45.63 | -24.07 | -6.46 | 43.79 | -17.77 |
| Cash & Equivalents | 289 | 186 | 124 | 152 | 76.52 | 3.31 |
| Total Debt | 2.47 | 0.52 | 0.49 | - | - | - |
| Net Cash / Debt | 286 | 186 | 124 | 152 | 76.52 | 3.31 |
| Assets | 299 | 197 | 132 | 156 | 79.93 | 30.30 |
| Liabilities | 26.81 | 18.93 | 15.17 | 13.72 | 8.89 | 6.83 |
| Book Value | 272 | 178 | 117 | 142 | 71.04 | 23.47 |
Company Profile
Company Details
| Full Name | AC Immune SA |
| Country | Switzerland |
| Employees | 115 |
| CEO | Andrea Pfeifer |
Stock Information
| Ticker Symbol | ACIU |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: ACIU |
| IPO Date | September 23, 2016 |
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.